

creos™

creos™ was launched in

2014

creos™ xenoprotect

2016

creos™ xenogain  
creos™ xenogain collagen

2018

creos™ mucogain

2021

creos™ syntoprotect

2022

creos™ syntogain  
creos™ xenoform

2023

creos™ syntostitch  
creos™ xenofill  
creos™ screw fixation  
creos™ xenofirm

2024

creos™ syntoprotect mesh

creos™

The trusted regenerative partner  
for you and your patients

Indication-based product overview 4

**Bone grafts**

creos™ xenogain	6
creos™ xenogain collagen	6
creos™ xenoform	8
creos™ syntogain	10

**Membranes**

creos™ xenoprotect	12
creos™ xenofirm	14
creos™ sytoprotect mesh	15
creos™ syntoprotect	16
creos™ syntoprotect titanium reinforced	16

**Collagen matrix**

creos™ mucogain	18
-----------------	----

**Wound dressings**

creos™ xenofill	20
-----------------	----

**Sutures**

creos™ syntostitch	22
--------------------	----

**Fixation systems**


creos™ screw fixation	23
-----------------------	----








Article overview 24

References 32

# Indication-based product overview

See article lists (p. 24–31) for most commonly used product codes



 Bone grafts	creos xenogain*	Xenogenic bone graft substitute	0.25–0.5 g	0.25–0.5 g	0.25–0.5 g	0.5–2 g	0.25–0.5 g	1–2 g	0.25 g	
	creos xenogain collagen	creos xenogain + 10% porcine collagen type I	0.1–0.25 g	0.1–0.5 g	0.25–0.5 g		0.15–0.25 g	0.25–0.5 g	0.1–0.25 g	
	creos xenoform*	Xenogenic bone graft substitute	0.25–0.5 g	0.25–0.5 g	0.25–0.5 g	0.5–2 g	0.25–0.5 g	1–2 g	0.25 g	
	creos syntogain*	Synthetic bone graft	0.5–1 g	0.5–1 g	0.5–1 g	1 g	0.5 g	1 g	0.5 g	
 Membranes	creos xenoprotect	Resorbable collagen membrane	15 x 20 mm		15 x 20 mm 25 x 30 mm	25 x 30 mm 30 x 40 mm	15 x 20 mm	15 x 20 mm 25 x 30 mm	15 x 20 mm	
	creos xenofirm	Resorbable, firm collagen membrane	15 x 20 mm		15 x 20 mm 20 x 30 mm	20 x 30 mm 30 x 40 mm	15 x 20 mm	15 x 20 mm 20 x 30 mm	15 x 20 mm	
	creos syntoprotect	Non-resorbable high-density PTFE membrane		12 x 24 mm 12 x 30 mm 25 x 30 mm			12 x 24 mm 12 x 30 mm 25 x 30 mm			
	creos syntoprotect Ti-reinforced	Non-resorbable titanium-reinforced high-density PTFE membrane		Shapes 1 and 2	Shapes depending on defect	Shapes depending on defect	Shapes depending on defect			
 Mesh	creos syntoprotect mesh	Reinforced PTFE mesh			Shapes depending on defect	Shapes depending on defect	Shapes depending on defect			
 Matrices	creos mucogain	Absorbable collagen matrix								15 x 20 mm 25 x 30 mm
 Wound dressings	creos xenofill	Absorbable wound dressing		Plug (fully intact sockets only)						Foam, Tape (for donor site)
 Sutures	creos syntostitch	Non-absorbable PTFE suture–monofilament	All sizes	All sizes	All sizes	All sizes	All sizes	All sizes	All sizes	4-0; 5-0
 Fixation system	creos screw fixation	Self-drilling titanium fixation screws			All types	All types	Membrane fixation screws; Tenting screws			

**Note** See Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions. Volumes and sizes listed are to be used as approximations and may vary depending on the defect/patient.

\*Please consult article lists (p. 24–31) for conversion to volume (cc)




# creos™ xenogain

**Xenogenic bone graft used for guided bone regeneration and guided tissue regeneration**



## Three different methods of application:



Vial

Bowl

Syringe

## Similar to human bone


- Chemical composition: Ca/P ratio
- Interconnected macropores<sup>1,2</sup>

## Easy handling

- Homogenous particle size<sup>1</sup>
- Hydrophilic for fast rehydration<sup>3,4</sup>

## Solid foundation for dental implant treatment

- Osteoconductive properties<sup>2</sup>
- Long-term volume stability<sup>6</sup>
- Uneventful healing<sup>7,8,4,6,9</sup>



"I appreciate its handling properties and I see its high hydrophilicity as a biological advantage in sinus grafting and peri-implant defect regeneration"

Dr. Werner Zechner, Austria



Bovine

# creos™ xenogain collagen



Block

Syringe

Purified cancellous bovine bone mineral granules and 10% porcine collagen in block form and syringe. The collagen helps to hold creos xenogain collagen in the desired place. Especially recommended for extraction socket management.



Bovine



Porcine

## Scaffold for successful regeneration

Preserved natural features of bone through optimized manufacturing process.<sup>2</sup>

### Chemical composition

With a calcium phosphate ratio that reflects the composition in human bone and a structure with low crystallinity, the body accepts creos xenogain as a suitable framework for bone formation.<sup>1</sup>

### Particle size

- Homogenous particle size<sup>1</sup>
- Maintains space for bone regeneration<sup>4</sup>


### Preserved nanostructure

Nanostructure preserved thanks to treatment at comparatively low temperature (600°C) and no sintering.<sup>2</sup>



### Macro and micro-structure

Interconnected macropores allow cells to invade bone grafts and micropores contribute to capillary liquid uptake (hydrophilicity).<sup>10,11</sup>

Calcium phosphate ratio




Photographic micrograph of creos xenogain and reference product showing the particle size distribution (magnification 20x)

creos™ xenogain  
(0.2–1.0 mm)Reference product  
(0.25–1.0 mm)

## Solid foundation for implant placement

The graft integrates with the newly formed bone, building a basis for successful implant placement.<sup>4</sup>


Schematic showing the defect and bone size prior to and after GBR



In a multicenter clinical study involving 46 patients, bone increase after 8 months was 4.0 mm (+56.9 % gain) and 4.7 mm (51.0% gain) at 1 and 3 mm from the top of the crest, respectively.<sup>6</sup>

GBR led to robust bone regeneration during the 8 months of healing, enabling successful placement of 91 implants in 43 patients, with an average insertion torque of  $37.8 \pm 5.1$  Ncm.<sup>6</sup>

Histological cross section of the cellular components: new bone (NB), bone graft (XG). Bone-to-graft-particle contact shown by dashed line.



Histological assessment of the trephine cores showed 37.3 % of new bone, 39.1 % of graft material, and 23.6 % of soft tissue (n = 6 cores, 3 patients).<sup>6</sup>



Scan the code for more resources.



# creos™ xenoform


**Xenogenic bone graft used for guided bone regeneration and guided tissue regeneration**

**Cancellous bovine bone sourced from Australia with two application types and two granule sizes**




## Multiporosity structure

- Made from 100% cancellous bone
- Innovative pulverizing technique allowing multiporous structure
- **Maximizing blood vessel ingrowth**




## Natural surface topography

- Low-temperature processing technique
- **Stimulating osteoblast activity**



## Large pore size

- creos xenoform has a relatively large pore size (300–400 µm) compared to other world-leading products
- **Favorable for blood vessel access and development<sup>1,2</sup>**




## Octacalcium phosphate crystals

- Found on the surface
- **Enhancing bone regeneration and formation<sup>1</sup>**


<sup>1</sup>as shown in an animal model

## Histology: New bone formation of the grafted creos xenoform in the human maxillary sinus cavity<sup>3</sup>

- Sinus graft procedures were conducted in 10 patients
- 6 specimens used for histomorphometric analysis
  - 23.5% new bone and 15.4% residual graft material 6 months after bone graft surgery
  - More newly formed bone than residual graft material




A. Residual graft material (\*) circumscribed by newly formed bone.



B. Ingrowth of microvessels in the newly formed bone (arrow) with lacunae in the bone lamellae.

## High percentage of newly regenerated bone

- Patient biopsies show  $23.5 \pm 0.1\%$  new bone vs  $15.4 \pm 0.06$  residual bone graft 6–8 months post sinus lift.<sup>3</sup>
- In an in-vivo model to evaluate the bone healing effect of biomaterials, the percentage of the newly formed bone with creos xenoform and the reference product were comparable (differences were statistically non-significant). No infections or complications observed after surgery.<sup>1</sup>



## Long-term success in clinical setting

In the last 10+ years, creos xenoform has been used by dental surgeons around the world and in challenging clinical.



Image courtesy of Myung Ho Lee, DDS, Republic of Korea



Scan the code for more resources.

# creos™ syntogain

## Non-animal-based bone graft substitute for efficient regeneration

### Unique composition of the material<sup>1,2,3</sup>

- 80% of calcium-deficient hydroxyapatite (CDHA) and 20% of BTCP (beta-tricalcium phosphate)
- It's biomimetic: it mimics human bone that is also made of CDHA<sup>1,2,3</sup>

### Microscopic surface made of nanocrystals<sup>1,4</sup>

- High specific surface area<sup>1,5,6</sup>: helps cells attach for new bone generation<sup>7</sup>
- High microporosity, thus enhancing bone ingrowth<sup>1,8</sup>

### Bone stability<sup>1,10</sup>

- The bone is stable and it maintains the volume of the defect based on clinical case series<sup>9,10</sup>

### And even more:

Granules have unique round shape<sup>1,10</sup>

- Makes it easy to apply in situ<sup>11</sup>
- Avoids stacking effect<sup>1</sup>

High hydrophilicity<sup>12</sup>

- Allows for easy hydration and granule handling<sup>12</sup>

Non-sintered<sup>1</sup>

- Microporosity and osteoconductivity are not reduced<sup>13,14</sup>



## Advanced manufacturing process<sup>1</sup>


creos syntogain is the latest generation of synthetic bone graft. Its manufacturing process in an aqueous environment and at low temperature enables a bone graft with a unique composition, round granule shapes, a high surface area and a nano-/microporosity similar to natural bone.

### 1. Unique composition<sup>1,2,3</sup>


- 80% CDHA (carbonated calcium deficient hydroxyapatite)
- 20%  $\beta$ -tricalcium phosphate.

creos syntogain CDHA crystallinity resembles that of human bone.<sup>1,2,3</sup>

The closer a material resembles human bone, the better it is for bone formation.<sup>15</sup>




**Current synthetics**  
Traditional calcium phosphate (HA / B-TCP) synthetics  
High-temperature manufacturing process: passivates materials and reduces the potential of the host to interact with it.



**Biomimetic**  
creos syntogain biomimetic calcium phosphate (CDHA / B-TCP)  
Low-temperature manufacturing process: hydroxyapatite crystals grow slowly to mimic the structure and composition of human bone.

### 2. High specific surface area<sup>1,5,6</sup>

Thanks to the biomimetic manufacturing process, hydroxyapatite crystals grow on the surface of the granules. This increases the surface area and enables the cells to attach for bone generation.<sup>16</sup>




The specific surface area was measured by nitrogen adsorption

## Clinical outcomes<sup>17</sup>

In one of the largest randomized clinical trials performed in dental bone regeneration with 102 patients in need of a bone augmentation, creos syntogain showed non-inferiority with the reference deproteinized bovine bone matrix (DBBM): no statistically significant difference in the vertical and buccolingual dimensional change was observed.

Six months post-grafting, the mean bone change in width and height was respectively -1.78% and 1.35% for creos syntogain (n=42) and -2.16% and 2.99% for the reference DBBM (n=41). The differences between the two materials were not statistically significant.



The mean implant insertion torque was 36.2 Ncm at sites regenerated with creos syntogain and 35.1 Ncm at sites regenerated with the reference DBBM. For creos syntogain, 71.1% of the implants were placed with an insertion torque above 35 Ncm and 62.8% for the reference DBBM.

	creos™ syntogain n=45	Reference DBBM	t-test
Insertion Torque (Ncm <sup>1</sup> )	36.2	35.1	0.676
StDev	12.4	13.6	
ISQ	70.2	70.8	0.770
StDev	12.0	9.8	



Scan the code for more resources.



# creos™ xenoprotect

**Nobel Biocare's highest selling  
resorbable collagen membrane**

## Easy handling<sup>1,2</sup>

- Does not stick to instruments
- Repositioning in-situ possible
- Low surface expansion when hydrated
- Both sides can face the defect

## High mechanical strength<sup>2,3,4</sup>

- High suture retention<sup>1,4,9</sup>
- Highly tear-resistant

## Natural collagen membrane

- Non-chemically cross-linked<sup>14</sup>
- Made from porcine collagen


## Facilitates bone gain<sup>2,3,5,6,7,8</sup>

- Tested and approved biocompatibility<sup>7,10</sup>
- Beneficial clinical results<sup>7,10</sup>



"What I like is that the handling is very easy. The mechanical stability is very high and when it is rehydrated it adapts very well to the underlying bone"

Dr. Bastian Wessing, Germany



\* As shown in an animal model (rat, subcutaneous)




## High mechanical strength

In an in vitro study aiming to compare the mechanical strength of commonly used native non-chemically cross-linked and chemically cross-linked collagen membranes<sup>4</sup>

- creos xenoprotect demonstrated the highest force at break, wet (21.2 N).
- creos xenoprotect had the highest suture retention when hydrated (6.1 N).

Comparison of commercial membranes in a hydrated state




Non-cross-linked collagen membranes (NXL) – CX: creos™ xenoprotect [Nobel Biocare]; CO: Copios [Zimmer]; JS: Jason [botiss]; OF: Osseoguard Flex [3i]; BG: Bio-Gide [Geistlich]

Cross-linked collagen membranes (XL) – BE: BioMend Extend [Zimmer]; ML: Mem-Lok [BioHorizons]; OP: OssixPlus [Datum Dental]; BM: BioMend [Zimmer];

\*Statistically significant

## Facilitates new bone formation<sup>2,3,5,6,7,8</sup>

New bone formation (%)



In a comparative in vivo study, creos xenoprotect demonstrated significantly higher new bone formation in the central portion of the defect.

This increase in bone formation was associated with significantly increased expression of the growth factor *Bmp2*, which has a strong role in osteogenesis.<sup>7</sup>


\*Statistically significant

## Provides a physical barrier to contain the bone graft material at the defect site<sup>1,2,3,5,6,11,12,13</sup>

Prevents ingrowth of surrounding tissue for a period of time that is long enough to allow bone regeneration to take place.

In an animal model, after 20 weeks, the thickness of xenoprotect decreased only slightly, whereas the reference membrane showed a thickness loss of around 50%, confirming the higher stability of xenoprotect against biodegradation in vivo.<sup>3</sup>


Representative histological images at 20 weeks implantation in a rat model.



In a randomized controlled clinical trial, 24 patients were treated with creos xenoprotect and 25 with a reference membrane. In the creos xenoprotect group, the defect height reduced at 6-month re-entry by 81%.

In the reference membrane group, the defect height reduced at 6-month re-entry by 62%.<sup>5</sup>

Schematic showing the defect height prior to treatment and 6 months after GBR



Scan the code for more resources.

# creos™ xenofirm

Resorbable, firm, and long-lasting collagen membrane

## Optimized flexibility

- Stiff enough for easy placement, yet easily drapes over ridge

## Long predictable resorption time

- Resorption time 26–30 weeks

## High tensile strength

- Suture or tack the membrane in place without tearing

## Manufactured from highly purified Type 1 bovine Achilles tendon

Reconstituted fiber construction allows tissue integration while preventing direct passage of epithelial cells.



Bovine

# creos™ syntoprotect mesh

Non-resorbable reinforced PTFE mesh for the stabilization and support of bone grafts in horizontal and vertical ridge augmentations

## Adaptability of a membrane with porosity of a mesh

Maintains space essential for horizontal and vertical ridge augmentations, but with the benefits of easier trimming and adaptation.

## Handling options

15 shapes adapted to treat different indications.

## Unique macroporous design


Direct contact between bone graft and periosteum allows naturally occurring revascularization and infiltration of cells into the bone graft.



Synthetic

## Vertical bone augmentation using a reinforced PTFE mesh<sup>1</sup>


A study published by Urban et al. that included 57 patients (65 defects) found that the mean absolute bone gain after vertical bone augmentation with a reinforced PTFE mesh was  $5.2 \pm 2.4$  mm, with a relative gain of  $96.5 \pm 13.9\%$ . Overall, 89.2% of cases showed complete regeneration.



Baseline vertical deficiency  $5.5 \pm 2.6$  mm



Vertical bone augmentation using a reinforced PTFE mesh



Mean absolute bone gain  $5.2 \pm 2.4$  mm  
Relative gain  $96.5 \pm 13.9\%$



"The creos PTFE mesh allows the vascularization you get from a mesh, but with the softness of a membrane that remains kind to soft tissues. With the mesh, and the bone quality I see at seven months, I am able to shorten time to implants by about two months."

Istvan Urban DMD, MD, PhD



Scan the code for more resources.



# creos™ syntopprotect

**Non-resorbable dense PTFE membrane for extraction socket management, ridge augmentations, and grafting of large defects**



## Purposely leave the membrane exposed

Preserves soft tissue architecture and keratinized mucosa

## Non-resorbable

Will not resorb prematurely – you dictate healing time


## syntopprotect PTFE membrane

### 100% dense (non-expanded) PTFE

Impervious to bacteria – pore size less than 0.3 µm

### Soft tissue attaches, but doesn't grow through the membrane

Exposed membrane allows for non-surgical removal; no anesthesia required



## syntopprotect Ti-reinforced PTFE membrane

### Delicate, lightweight framework

Easy to trim and compliant with the overlying soft tissues

### Less is more

Less titanium bulk allows for greater versatility in shaping and placement, providing additional stability in large, non-spacemaking osseous defects

### Handling options

Broad portfolio with 15 shapes in two thicknesses


### Traditional frame design

Incorporating delicate and strategically-placed titanium "struts" with more than 25 years of clinical history and successful use in GBR




## Unique properties of dense PTFE membranes

### Dense PTFE



SEM image courtesy of Schüpbach Ltd, Switzerland.


### Expanded PTFE



SEM image courtesy of Schüpbach Ltd, Switzerland.


Dense PTFE was designed to withstand exposure in the oral environment, which represents an improvement to earlier versions of expanded PTFE in applications such as ridge preservation where deliberate membrane exposure offers several advantages.

## Designed to aid in membrane stabilization



SEM image courtesy of Schüpbach Ltd, Switzerland.

Hexagonal surface dimples provide a textured surface that increases the area available for cellular attachment without increasing porosity. The textured surface is designed to help stabilize the membrane and the soft tissue flap.




Although PTFE is inherently a non-stick material, cells attach to the outside of the dense PTFE membranes. Cellular adhesion is important to create a seal around the edges of exposed dense PTFE membranes or to support primary closure in larger graft applications.

## Clinical evidence


### Efficacy

Bone loss 1-year post-extraction<sup>1</sup>




Vertical bone loss measured at crest. Horizontal measured from stent to buccal plate.

Soft tissue regeneration 90 days post-extraction<sup>2</sup>



Measured as reduction of the occlusal distance between buccal and lingual gingival margins.

Vertical ridge augmentation around implants<sup>3</sup>



Mean vertical bone regeneration.

### Predictability

In two separate studies treating a total of 696 extraction sites using dense PTFE membranes in an exposed technique, there were no reported infections.<sup>4,5</sup>



Scan the code for more resources.

# creos™ mucogain

Collagen matrix designed to promote soft tissue regeneration

Substitutes the need for a second surgical site<sup>1,2,3</sup>

## Patented manufacturing method

- Open interconnecting porous structure.
- Designed to promote soft tissue regeneration through the migration of cells and blood vessels into the matrix.<sup>4,5,6</sup>

## Variety of choices


- A choice of different sizes and thicknesses.

## Excellent handling

- Easy to use<sup>7</sup>
- High suture retention and stress resistance<sup>7</sup>
- Memory effect after hydration and cycling loading in vitro<sup>4</sup>
- Trim to precisely fit surgical site<sup>7</sup>

## Clinically effective

- Shown to promote soft tissue health and maintain adequate soft tissue thickness in a clinical study.<sup>23,24,25,26</sup>



"It felt like an autogenous tissue graft and the mechanical stability is amazing"

Dr. Miguel González Menéndez, Spain




Porcine

## Use straight out of the box

creos mucogain is intended to be used for soft tissue augmentation indications in the oral cavity around teeth or implants:


- Guided tissue regeneration (GTR) procedures in recession defects for root coverage.
- Localized gingival augmentation to increase keratinized tissue around teeth and implants.




## Unique oriented porous structure



**1. Matrix structure**  
Interconnecting porous structure produced by a patented process.<sup>4,5,6</sup>



**2. Mechanical properties**  
After hydration and compression in 49 cycles in vitro, the graft regains its initial volume.<sup>4</sup>



**3. Biological outcome**  
Designed to promote soft tissue regeneration through the migration of cells and blood vessels into the matrix.<sup>4,6</sup>

## Clinically effective<sup>7,8,9,10</sup>

Clinically effective for soft tissue regeneration in combination with immediate implant placement and bone grafting procedure.<sup>7,8</sup>

A retrospective analysis including 45 patients with a follow-up of up to 4.5 years (mean of  $1.8 \pm 1.3$  years) demonstrated that creos mucogain promotes soft tissue health and maintains adequate soft tissue thickness when used simultaneously with implant placement.<sup>9</sup>

## Clinical case

Buccal view prior to surgery (left) and 8 months after surgery (right) on #22, #24, #25, #26 after treatment with creos mucogain.



Cirillo F. (March 2020). Periodontal plastic surgery: gingival recession coverage with a xenogenic collagen matrix. The Foundation for Oral Rehabilitation (FOR.org): <https://bit.ly/2TkLsgu> (Images reprinted with permission of the author and FOR.)



Scan the code for more resources.




# creos™ xenofill

**Absorbable wound dressings to protect wound beds and aid in wound healing**

**Available in 3 shapes and sizes**

**Made from purified collagen derived from bovine tissue**

**Essentially resorbs in 30 days**



**Tape**  
2.5 cm x 7.5 cm x 1 mm (thick)



**Plug**  
1 cm x 2 cm



**Foam**  
2 cm x 4 cm x 3 mm (thick)

## Applications:

- Surgical wounds
- Periodontal surgical wounds
- Extraction sites
- Dental sores
- Oral ulcers (non-infected or viral)
- Suture sites
- Burns
- Traumatic wounds




Scan the code for more resources.




# creos™ syntostitch

**Non-absorbable monofilament  
PTFE sutures**

## Smooth monofilament rod



creos™ syntostitch  
350x magnification



PTFE competitor  
350x magnification

**100% medical-grade PTFE** Biologically inert

**Monofilament** Does not wick bacteria

**Soft (not stiff)** Comfortable for patients


**Little to no package memory** Excellent handling, knots securely

**Non-resorbable** Keeps the surgical site reliably closed

## Advantages of the 300 series stainless steel needles:


- Gold standard material for suture needles
- Increased needle strength and needle sharpness
- Less force to penetrate

## Resistance to bending




\*common in dentistry


## Needle shapes



## Thread diameters




## Recommended knot<sup>1</sup>



# creos™ screw fixation

**Instruments and screws for fast  
and easy placement of membrane,  
bone block, and tenting screws**



## One kit for three types of screws

- Variety of membrane fixation, bone fixation, and tenting screws
- Instruments designed to work universally with all creos screw fixation screw types

## Self-drilling screws

- The self-drilling design of the membrane fixation and tenting screws allows penetration through cortical bone without the use of a mallet or the need for drilling pilot holes

## Stable and secure fixation

- Easy pick-up, solid stability of the screw during transfer to the surgical site, and easy placement make membrane fixation fast and easy



**Membrane  
fixation screws**  
Secure membranes  
and mesh



**Tenting screws**  
Maintain space under  
membranes in horizontal  
and vertical augmentation  
procedures



**Bone fixation screws**  
Stabilize, fixate, and support  
bone block grafts



**Contra-angle blade  
(optional)**  
Designed for posterior and  
lingual screw placement,  
it attaches to latch type  
motorized hand pieces  
and works universally  
with all creos screws



# Products

## creos™ xenogain

Xenogenic bone graft substitute

Weight	Granule size	Volume	Vial	Bowl	Syringe
0.25 g	Small (0.2–1.0 mm)	0.36 cc	N1110	N1110-B	N1210
	Large (1.0–2.0 mm)	0.54 cc	N1111	N1111-B	N1211
0.5 g	Small (0.2–1.0 mm)	0.82 cc	N1120	N1120-B	N1220
	Large (1.0–2.0 mm)	1.27 cc	N1121	N1121-B	N1221
1.00 g	Small (0.2–1.0 mm)	1.71 cc	N1130	N1130-B	
	Large (1.0–2.0 mm)	2.69 cc	N1131	N1131-B	
2.00 g	Small (0.2–1.0 mm)	3.64 cc	N1140	N1140-B	
	Large (1.0–2.0 mm)	5.74 cc	N1141	N1141-B	




## creos™ xenogain collagen

creos™ xenogain + 10% porcine collagen type I



Weight	Block size	Article no.
0.1 g	6 × 6 × 6 mm	N1320
0.25 g	7 × 8 × 9 mm	N1330
0.5 g	9 × 10 × 11 mm	N1340



Weight	Syringe size	Article no.
0.25 g	4.6 × 40 mm	N1410
0.5 g	5.6 × 45 mm	N1420



### Symbol glossary


-  Temperature limit
-  Upper limit of temperature

### Most commonly sold articles

## creos™ xenoform

Xenogenic bone graft substitute

Weight	Granule size	Volume	Vial (Granules)	Syringe
0.25 g	0.2–1.0 mm	0.5 cc	CHY25-0210	CHYS25-0210
0.5 g		1.1 cc	CHY05-0210	CHYS05-0210
1.0 g		2.1 cc	CHY10-0210	
2.0 g		4.1 cc	CHY20-0210	
0.25 g	0.5–1.2 mm	0.6 cc	CHY25-0512	CHYS25-0512
0.5 g		1.2 cc	CHY05-0512	CHYS05-0512
1.0 g		2.3 cc	CHY10-0512	
2.0 g		4.5 cc	CHY20-0512	



## creos™ syntogain

Synthetic bone graft

Weight	Granule size	Volume	Vial
0.5 g	Small (0.2–1.0 mm)	0.50 cc	S1110
1.0 g	Small (0.2–1.0 mm)	1.00 cc	S1120
0.5 g	Large (1.0–2.0 mm)	0.50 cc	S1111
1.0 g	Large (1.0–2.0 mm)	1.00 cc	S1121



## creos™ xenoprotect

Nobel Biocare’s highest selling  
resorbable collagen membrane


Size	Article no.
15 × 20 mm	E1520
25 × 30 mm	E2530
30 × 40 mm	E3040



## creos™ xenofirm

Resorbable, firm, collagen membrane


Size	Units/box	Article no.
15 × 20 mm	2	CLMCM1520
20 × 30 mm	2	CLMCM2030
30 × 40 mm	2	CLMCM3040



## creos™ syntoprotect PTFE membrane

Non-resorbable, high-density PTFE membrane


Shape	Picture	Size	Thickness	Article no.	Units/box	Description
Small		12 × 24 mm	200 µm	N161224-1	1	Designed specifically for extraction site grafting and augmentation procedures where exposure to the oral cavity is common
			200 µm	N161224-10	10	
Medium		12 × 30 mm	200 µm	N161230-10	10	
Large		25 × 30 mm	200 µm	N162530-1	1	
			200 µm	N162530-4	4	



## creos™ syntoprotect Ti-reinforced PTFE membrane

Non-resorbable, titanium reinforced, high-density PTFE membrane

Shape	Picture	Size	Thickness	1 unit per box	2 units per box	Description
No. 1		12 × 24 mm	150 µm	N1615TI-01-1	N1615TI-01-2	Designed for narrow single-tooth extraction sites, especially where one bony wall is missing
			250 µm	N1625TI-01-1	N1625TI-01-2	
No. 1, 30 mm		12 × 30 mm	150 µm	n/a	n/a	
			250 µm	N1625TI-01-30-1	N1625TI-01-30-2	
No. 2		14 × 24 mm	150 µm	N1615TI-02-1	N1615TI-02-2	Designed for single-tooth extraction sites, especially where one or more bony walls are missing
			250 µm	N1625TI-02-1	N1625TI-02-2	
No. 3		17 × 25 mm	150 µm	N1615TI-03-1	N1615TI-03-2	Designed for large buccal defects
			250 µm	N1625TI-03-1	N1625TI-03-2	
No. 3, 30 mm		17 × 30 mm	150 µm	N1615TI-03L-1	N1615TI-03L-2	
			250 µm	N1625TI-03L-1	N1625TI-03L-2	
No. 4		20 × 25 mm	150 µm	N1615TI-04-1	N1615TI-04-2	Designed for large extraction sites and limited ridge augmentation
			250 µm	N1625TI-04-1	N1625TI-04-2	
No. 5		36 × 25 mm	150 µm	N1615TI-05-1	N1615TI-05-2	Designed for large extraction sites and limited ridge augmentation in the anterior maxilla
			250 µm	N1625TI-05-1	N1625TI-05-2	
No. 6		25 × 30 mm	150 µm	N1615TI-06-1	N1615TI-06-2	Designed for large bony defects, including ridge augmentation
			250 µm	N1625TI-06-1	N1625TI-06-2	
No. 7		30 × 41 mm	150 µm	N1615TI-07-1	N1615TI-07-2	Designed for large bony defects, including ridge augmentation in the anterior maxilla
			250 µm	N1625TI-07-1	N1625TI-07-2	
No. 8		30 × 40 mm	150 µm	N1615TI-08-1	N1615TI-08-2	Designed for very large bony defects, including ridge augmentation
			250 µm	N1625TI-08-1	N1625TI-08-2	
No. 9		30 × 40 mm	150 µm	N1615TI-09-1	N1615TI-09-2	Designed for very large bony defects, including ridge augmentation
			250 µm	N1625TI-09-1	N1625TI-09-2	
No. 10		24 × 38 mm	150 µm	N1615TI-10-1	N1615TI-10-2	Designed for large extraction sites, including ridge augmentation
			250 µm	N1625TI-10-1	N1625TI-10-2	
No. 11		38 × 38 mm	150 µm	N1615TI-11-1	N1615TI-11-2	Designed for large bony defects, including ridge augmentation
			250 µm	N1625TI-11-1	N1625TI-11-2	
No. 12		38 × 38 mm	150 µm	N1615TI-12-1	N1615TI-12-2	Designed for large bony defects, including distal extension of the posterior ridge
			250 µm	N1625TI-12-1	N1625TI-12-2	
No. 13		40 × 50 mm	150 µm	N1615TI-13-1	N1615TI-13-2	Designed for the largest bony defects, including ridge augmentation
			250 µm	N1625TI-13-1	N1625TI-13-2	






# creos™ syntoprotect mesh

Non-resorbable mesh


Shape	Picture	Size	Thickness	1 unit per box	Description
No. 3		17 × 25 mm	200 µm	301871	Designed for large buccal defects
No. 3, 30 mm		17 × 30 mm	200 µm	301892	
No. 4		20 × 25 mm	200 µm	301872	Designed for large extraction sites and limited ridge augmentation
No. 5		36 × 25 mm	200 µm	301873	Designed for large extraction sites and limited ridge augmentation in the anterior maxilla
No. 6		25 × 30 mm	200 µm	301874	Designed for large bony defects, including ridge augmentation
No. 7		30 × 41 mm	200 µm	301875	Designed for large bony defects, including ridge augmentation in the anterior maxilla
No. 8		30 × 40 mm	200 µm	301876	Designed for very large bony defects, including ridge augmentation
No. 9		30 × 40 mm	200 µm	301877	Designed for very large bony defects, including ridge augmentation
No. 9M		30 × 40 mm	200 µm	301878	
No. 10		24 × 38 mm	200 µm	301879	Designed for large extraction sites, including ridge augmentation
No. 10M		24 × 38 mm	200 µm	301880	
No. 11		38 × 38 mm	200 µm	301881	Designed for large bony defects, including ridge augmentation
No. 11M		38 × 38 mm	200 µm	301882	
No. 12		38 × 38 mm	200 µm	301883	Designed for large bony defects, including distal extension of the posterior ridge
No. 13		40 × 50 mm	200 µm	301886	Designed for the largest bony defects, including ridge augmentation



# creos™ mucogain

Absorbable collagen matrix


Size	Block size	Article no.
15 × 20 mm	3 mm	MU15203
25 × 30 mm	3 mm	MU25303
15 × 20 mm	5 mm	MU15205
25 × 30 mm	5 mm	MU25305



# creos™ xenofill

Absorbable wound dressing



Size	Size	Units/box	Article no.
Plug	1 × 2 cm	10	CLMBDDWDP1020
Foam	2 × 4 cm	10	CLMBDDWDF2040
Tape	2.5 × 7.5 cm	10	CLMBDDWDT2575



# creos™ syntostitch


Non-absorbable PTFE suture – monofilament

Needle shape	USP	Needle size	Needle color	Suture length 45 cm 12 units per box	Suture length 70 cm 12 units per box
TP 1/2 circle Round-bodied	4-0	13 mm		301815	301816
		19 mm		301805	301806
		16 mm		301807	301808
	3-0	19 mm		301809	301810
		16 mm	black	301811	301812
RC 3/8 circle Precision reverse cutting		19 mm	black	301813	301814
		13 mm		301817	301818
	4-0	16 mm		301819	301820
		13 mm		301821	301822
	5-0	16 mm		301823	301824



# creos™ screw fixation

Titanium screws for membrane/bone fixation and tenting



### Stabilization kit includes

- Storage tray with screw organizer dial
- Stainless steel driver handle
- 76 mm cruciform driver blade
- 56 mm cruciform driver blade



### Contra angle driver blade

Description	Article no.
24 mm	301802

### Individual components

Description	1 unit per box
Cruciform driver blade, 76 mm	301800
Cruciform driver blade, 56 mm	301801
Stainless steel driver handle	301803
Autoclavable storage tray	301804

### Membrane fixation kit Article 301779

Products included	Size	QTY
Stabilization kit		1
Self-drilling membrane fixation screw	1.5 x 3 mm	20

### Tenting kit Article 301782

Products included	Size	QTY
Stabilization kit		1
	1.5 x 3 mm	4
Self-drilling tenting screw	1.5 x 4 mm	4
	1.5 x 5 mm	4

### Bone fixation kit Article 301791

Products included	Size	QTY
Stabilization kit		1
	1.5 x 8 mm	2
Self-tapping bone fixation screw	1.5 x 10 mm	4
	1.5 x 12 mm	4
	1.5 x 14 mm	2


### Membrane fixation screws

Size	5 units per box
1.5 x 3 mm	301780
1.5 x 5 mm	301781




### Tenting screws

Size	Special	1 unit per box	5 units per box
1.5 x 3 mm polished neck		301783	301784
1.5 x 4 mm polished neck	+4 mm threaded portion	301785	301786
1.5 x 5 mm polished neck		301787	301788
1.5 x 8 mm	fully threaded	301789	n/a
1.5 x 10 mm	fully threaded	301790	n/a



### Bone fixation screws

Size	1 unit per box	5 units per box
1.5 x 8 mm	301792	301793
1.5 x 10 mm	301794	301795
1.5 x 12 mm	301796	301797
1.5 x 14 mm	301798	301799



All measurements in millimeters.



Connect to Nobel Biocare Online store



# References

## creos™ xenogain

1. Nobel Biocare, data on file.

2. Rhee S-H, Park HN, Seol Y-J et al. Effect of heat-treatment temperature on the osteoconductivity of the apatite derived from bovine bone. 2006 Key Engineering Materials 309-311:41-44 [Read](#)

3. Arrighi I, Wessing B, Rieben A, et al. Resorbable collagen membranes expansion in vitro. J Dent Res 2014;93 (Spec Iss B):631 [Read on Pubmed](#)

4. Park JB, et al. Maxillary sinus floor augmentation using deproteinized bovine bone-derived bone graft material (OCS-B). Clinical and histologic findings in humans. The Journal of the Korean Dental Association. 2007;45(8):491–99 [Read on Pubmed](#)

5. Shin S-Y, et al. Long-term results of new deproteinized bovine bone material in a maxillary sinus graft procedure. J Periodontal Implant Sci. 2014;44:259-64. [Read on Pubmed](#)

6. Aleksic Z, Milikovic I, Lazic Z, et al. A multicenter clinical investigation demonstrates bone regeneration in severe horizontal defects in the posterior mandible using creos™ xenoprotect: Interim results. J Clin Periodontol 2018;45(S19):306 [Read](#)

7. Park HN, Han, SH, Kim KW, et al. A study on the safety and efficacy of bovine bone-derived bone graft material (OCS-B). J Korean Acad Periodontol. 2005 Jun;35(2):335 – 43 [Read](#)

8. Kim Y-T, et.al. Periodontal Repair on Intrabony Defects treated with Anorganic Bovine-derived Xenograft.J Korean Acad Periodontol. 2007;37(3):489 – 96

9. Fernandez de Grado G, Keller L, Idoux-Gillet Y et al. Bone substitutes: a review of their characteristics, clinical use, and perspectives for large bone defects management. Journal of Tissue Engineering Volume 9: 1–18, 2018 [Read on Pubmed](#)

10. Zhang K, Fan Y, Dunne N et al. Effect of microporosity on scaffolds for bone tissue engineering. Regenerative Biomaterials, 2018, 115–124 [Read on Pubmed](#)

## creos™ xenoform

1. Suzuki O, Shiwaku Y, Hamai R. Octacalcium phosphate bone substitute materials: Comparison between properties of biomaterials and other calcium phosphate materials. Dent Mater J. 2020;39(2):187-199. doi:10.4012/dmj.2020-00 [Read on Pubmed](#)

2. Anil A, Sadasivan A, Koshi E. Physicochemical Characterization of Five Different Bone Graft Substitutes Used in Periodontal Regeneration: An In Vitro Study. J Int Soc Prev Community Dent. 2020;10(5):634-642. Published 2020 Sep 28. doi:10.4103/jispcd.JISPCD\_263\_20 [Read](#)

3. JH. Lee, JH Kim, JHong Jeon, Bone Regeneration of Macropore Octacalcium Phosphate–Coated Deproteinized Bovine Bone Materials in Sinus Augmentation: A Prospective Pilot Study, Implant Dentistry, 2015;24(3):275-280 [Read on Pubmed](#)

## creos™ syntogain

1. Hoornaert A, Maazouz Y, Pastorino D, et al. Vertical Bone Regeneration with Synthetic Biomimetic Calcium Phosphate onto the Calvaria of Rats. Tissue Eng Part C Methods. 2019 Jan;25(1):1-11. doi: 10.1089/ten.TEC.2018.0260. PMID: 30501579. [Read on Pubmed](#)

2. Barba A, Diez-Escudero A, Espanol M, et al. Impact of biomimicry in the design of osteoinductive bone substitutes: nanoscale matters. ACS Appl. Mater. Interfaces 2019. DOI:10.1021/acsami.8b20749. [Read on Pubmed](#)

3. Data on file: Mimetis XRD analysis report using the RIR quantification method. Medical device composition certificate.

4. Barba A, Diez-Escudero A, Maazouz Y, et al. Osteoinduction by foamed and 3D-printed calcium phosphate scaffolds: effect of nanostructure and pore architecture. ACS Appl. Mater. Interfaces 2017. DOI:10.1021/acsami.7b14175. [Read on Pubmed](#)

5. Sadowska JM, Guillem-Marti J, Montufar EB, Espanol M, Ginebra MP. \* Biomimetic Versus Sintered Calcium Phosphates: The In Vitro Behavior of Osteoblasts and Mesenchymal Stem Cells. Tissue Eng Part A. 2017 Dec;23(2324):1297-1309. doi: 10.1089/ten.TEA.2016.0406. Epub 2017 Feb 21. PMID: 28107811. [Read on Pubmed](#)

6. Data on file: Milestone 2 study (page 18)

7. Konka J, Espanol M, Bosch BM, de Oliveira E, Ginebra MP. Maturation of biomimetic hydroxyapatite in physiological fluids: a physicochemical and proteomic study. Mater Today Bio. 2021 Sep 15;12:100137. doi: 10.1016/j.mtbio.2021.100137. PMID: 34632362; PMCID: PMC8487082. [Read on Pubmed](#)

8. Hannink G, Arts C. Bioresorbability, porosity and mechanical strength of bone substitutes: What is optimal for bone regeneration? Injury, Volume 42, Supplement 2, 2011, Pages S22-S25, ISSN 0020-1383. [Read on Pubmed](#)

9. Data on file: Clinical cases from 2022.

10. Raymond Y, Pastorino D, Ginebreda I, et al. Computed tomography and histological evaluation of xenogenic and biomimetic bone grafts in three-wall alveolar defects in minipigs. Clin Oral Investig. 2021 Dec;25(12):6695-6706. doi: 10.1007/s00784-021-03956-y. Epub 2021 May 1. PMID: 33931811. [Read on Pubmed](#)

11. Data on file: Granules handling Voice of Customer from 2017-2018 + GKEM Handling Questionnaires Results from 2022.

12. Data on file: Milestone 2 report (chapter 2.5.1)

13. Henkel KO, Gerber T, Lenz S, Gundlach KK, Bienengraber V. Macroscopical, histological, and morphometric studies of porous bone-replacement materials in minipigs 8 months after implantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Nov;102(5):606-13. doi: 10.1016/j.tripleo.2005.10.034. Epub 2006 May 19. PMID: 17052636. [Read on Pubmed](#)

14. Weibrich G, Trettin R, Gnoth SH, et al. Bestimmung der Größe der spezifischen Oberfläche von Knochenersatzmaterialien mittels Gasadsorption. (Alternate title: Analysis of the size of the specific surface area of one regeneration materials by gas adsorption). Mund Kiefer GesichtsChir (2000) 4:148-152 Springer-Verlag 2000. [Read](#)

15. Rufino Senra M, de Fátima Vieira Marques M. Synthetic Polymeric Materials for Bone Replacement. J. Compos. Sci. 2020,4, 191;doi:10.3390/jcs4040191. [Read](#)

16. Ginebra MP, Espanol M, Maazouz Y, Bergez V, Pastorino D. Bioceramics and bone healing. EFORT Open Rev 2018;3 DOI: 10.1302/2058-5241.3.170056. [Read on Pubmed](#)

17. Ginebra Cairó I., Roig Cayón M., Velasco-Ortega E. et al., Biomimetic synthetic bone graft in alveolar ridge preservation: 1-year RCT results, Abstract N°EAO-647 EAO Geneva 2022.

## creos™ xenoprotect

1. Aleksic Z. A multicenter clinical investigation demonstrates bone regeneration in severe horizontal defects in the posterior mandible using creos xenoprotect: Interim results. Conference: Europerio 9, July 2018. [Read](#)

2. Wessing B, Emmerich M, Bozkurt A. Horizontal ridge augmentation with a novel resorbable collagen membrane: a retrospective analysis of 36 consecutive patients. Int J Periodontics Restorative Dent 2016;36(2):179–187. [Read on Pubmed](#)

3. Bozkurt A, Apel C, Sellhaus B, et al. Differences in degradation behavior of two non-cross-linked collagen barrier membranes: an in vitro and in vivo study. Clin Oral Impl Res; 2014; 25(12):1403-1411 [Read on Pubmed](#)

4. Gasser A, Wessing B, Eummelen L, et al. Mechanical stability of collagen membranes: an in vitro study. J Dent Res 2016;95(Spec Iss A): 1683 [Read](#)

5. Wessing B, Urban I, Montero E, et al. A multicenter randomized controlled clinical trial using a new resorbable non-cross- linked collagen membrane for guided bone regeneration at dehiscd single implant sites: interim results of a bone augmentation procedure. Clin Oral Impl Res; 2017;28(11):e218–e226. [Read on Pubmed](#)

6. Sanz-Sanchez I, Wessing B, Polizzi G, et al. Randomized clinical trial comparing two resorbable collagen membranes demonstrates good bone formation and soft tissue healing with GBR at single implant sites with dehiscence defects. J Clin Periodontol 2018;45(S19):19–20 [oral presentation]. [Read](#)

7. Omar O, Dahlin A, Gasser A, et al. Tissue dynamics and regenerative outcome in two resorbable noncross- linked collagen membranes for guided bone regeneration: A preclinical molecular and histological study in vivo. Clin Oral Impl Res; 2018;29(1):7–19 [Read on Pubmed](#)

8. Aleksic Z, Milikovic I, Lazic Z, et al. A multicenter clinical investigation demonstrates bone regeneration in severe horizontal defects in the posterior mandible using creos™ xenoprotect: Interim results. J Clin Periodontol 2018;45(S19):306 [Read](#)

9. Raz P, Brosh T, Ronen G, Tal H. Tensile Properties of Three Selected Collagen Membranes. Biomed Res Int. 2019 Dec 5;2019:5163603. doi: 10.1155/2019/5163603. PMID: 31886222; PMCID: PMC6915138. [Read on Pubmed](#)

**10.** Jäger M, Degistirici O, Knipper A, Fischer J, Sager M, Krauspe R. Bone healing and migration of cord blood-derived stem cells into a critical size femoral defect after xenotransplantation. J Bone Miner Res. 2007;22(8): 1224-33. [Read on Pubmed](#)

**11.** Redemagni M, Mascetti T, Garlini G. Post-Extractive Immediate Implant Placement and Immediate Provisionalization at Sites Requiring Buccal Bone Regeneration:. EC Dental Science. 2019(18.6): 1207-16. [Read](#)

**12.** Cadenas-Vacas G, Martínez-Rodríguez N, Barona-Dorado C, Sánchez-Labrador L, Cortés-Bretón Brinkmann J, Meniz-García C, et al. Calcium Phosphate Modified with Silicon vs. Bovine Hydroxyapatite for Alveolar Ridge Preservation: Densitometric Evaluation, Morphological Changes and Histomorphometric Study. Materials (Basel) [Internet]. 2021;14(4): 940. [Read](#)

**13.** Bruyckere T de, Cosyn J, Younes F, Hellyn J, Bekx J, Cleymaet R, et al. A randomized controlled study comparing guided bone regeneration with connective tissue graft to reestablish buccal convexity: One-year aesthetic and patient-reported outcomes. Clin Oral Implants Res. 2020;31(6): 507-16. [Read on Pubmed](#)

**14.** J. Jiménez Garcia, S. Berghezan, J.M.M. Caramês, M.M. Dard, D.N.S. Marques, Effect of cross-linked vs non-cross-linked collagen membranes on bone: A systematic review, J Periodont Res. 2017;1–10. [Read on Pubmed](#)

Bruyckere T de, Eeckhout C, Eghbali A, Younes F, Vandekerckhove P, Cleymaet R, et al. A randomized controlled study comparing guided bone regeneration with connective tissue graft to re-establish convexity at the buccal aspect of single implants: A one-year CBCT analysis. J Clin Periodontol. 2018;45(11): 1375-87. [Read on Pubmed](#)

González Regueiro I, Martínez Rodríguez N, Barona Dorado C, Sanz-Sánchez I, Montero E, Ata-Ali J, et al. Surgical approach combining implantoplasty and reconstructive therapy with locally delivered antibiotic in the treatment of peri-implantitis: A prospective clinical case series. Clin Implant Dent Relat Res. 2021;23(6): 864-73. [Read on Pubmed](#)

## creos™ syntoprotect

**1.** Fotek PD, Neiva RF, Wang HL. Comparisonof dermal matrix and polytetrafluoroethylenemembrane for socket bone augmentation: a clinicaland histologic study. J Periodontol 2009;80:776-785. [Read on Pubmed](#)

**2.** Barboza EP, Francisco BS, Ferreira VF. Soft tissue enhancement using non-expanded PTFE membranes without primary closure [abstract]. Presented at the 2008 Research Forum Poster Session. Annual Meeting of the American Academy of Periodontology (AAP) in Seattle, WA, September 6-9, 2008.

**3.** Ronda M, Rebaudi A, Torelli L, Stacchi C. Expanded vs. dense polytetrafluoroethylene membranes in vertical ridge augmentation around dental implants: a prospective randomized controlled clinical trial. Clin Oral Impl Res; 2014 Jul;25(7):859-66. [Read on Pubmed](#)

**4.** Barboza EP, Stutz B, Ferreira VF, Carvalho W. Guided bone regeneration using nonexpanded polytetrafluoroethylene membranes in preparation for dental implant placements - a report of 420 cases. Implant Dent. 2010;19:2-7. [Read on Pubmed](#)

**5.** Hoffman O, Bartee BK, Beaumont C, Kasaj A, Deli G, Zafiropoulos GG. Alveolar bone preservation in extraction sockets using non-resorbable dense PTFE membranes: A retrospective non-randomized study. J Periodontol 2008;79:1355-1369. [Read on Pubmed](#)

## creos™ syntoprotect mesh

**1.** Urban IA, Saleh MHA, Ravidà A, Forster A, Wang HL, Barath Z. Vertical bone augmentation utilizing a titanium-reinforced PTFE mesh: A multi-variate analysis of influencing factors. Clin Oral Implants Res. 2021 Jul;32(7):828-839. [Read on Europe PMC](#).

**2.** Bettini S, Rengo C, Fiorino A, Cucchi A. Vertical Ridge Augmentation Using Reinforced PTFE Mesh Versus Customized Titanium Mesh. Preliminary Results Of A Randomized Clinical Trial. Poster presented at the 2020 IAO in Milan Italy. [Access the study](#).

## creos™ mucogain

**1.** Aguirre-Zorzano LA, García-De La Fuente AM, Estefanía-Fresco R, et al. Complications of harvesting a connective tissue graft from the palate. A retrospective study and description of a new technique. J Clin Exp Dent 2017;9(12):e1439-e1445. [Read on Pubmed](#)

**2.** Griffin TJ, Cheung WS, Zavras AI, et al. Postoperative complications following gingival augmentation procedures. J Periodontol 2006;77(12):2070-2079. [Read on Pubmed](#)

**3.** Harris RJ, Miller R, Miller LH, et al. Complications with surgical procedures utilizing connective tissue grafts: a follow-up of 500 consecutively treated cases. Int J Periodontics Restorative Dent 2005;25(5):449-459.C513 [Read on Pubmed](#)

**4.** Damink L.O., Heschel I, Leemhuis H. et al Gasser A, Wessing B, Eummelen L, et al. Soft tissue volume augmentation in the oral cavity with a collagen-based 3D matrix with orientated open pore structure. Current Directions in Biomedical Engineering 2018; 4(1): 237 – 241 References 1-10 11-20 [Read on Researchgate](#)

**5.** Heschel I, et al. 2002. Method for producing-porous structures. US patent 6,447,701 B1.

**6.** Boekema B., Vlig F, Damink O.L. et al. Effect of pore size and cross-linking of a novel collagenelastin dermal substitute on wound healing. J Mater Sci Mater Med 2014;25(2):423-433 [Read on Pubmed](#)7. Wessing B, Vasilic N. Soft tissue augmentation with a new regenerative collagen 3-D matrix with oriented open pores as a potential alternative to autologous connective tissue grafts. Clin Oral Impl Res; 2014 Sep;25(s10)

**8.** Sanz-Martin I, Encalada C, Sam-Sanchez I, et al. Soft tissue augmentation at immediate implants using a novel xenogeneic collagen matrix in conjunction with immediate provisional restorations: A prospective case series. Clin Implant Dent Relat Res 2019;21(1):145-153. [Read on Pubmed](#)

**9.** Cirillo F and Encalada C. Periodontal plastic surgery: treatment of multiple gingival recessions. FOR.org [Read on FOR.org](#)

## creos™ xenofill

Basma, H. S., Saleh, M. H. A., Abou-Arroj, R. V., Imbrogno, M., Ravida, A., Wang, H. L., Li, P., & Geurs, N. (2023). Patient-reported outcomes of palatal donor site healing using four different wound dressing modalities following free epithelialized mucosal grafts: A four-arm randomized controlled clinical trial. Journal of periodontology, 94(1), 88–97. [Read on Pubmed](#)

## creos™ syntostitch

**1.** Abellán, D., Nart, J., Pascual, A., Cohen, R. E., & Sanz-Moliner, J. D. (2016). Physical and Mechanical Evaluation of Five Suture Materials on Three Knot Configurations: An in Vitro Study. Polymers, 8(4), 147. [Read](#)

Taysi AE, Ercal P, Sismanoglu S. Comparison between tensile characteristics of various suture materials with two suture techniques: an in vitro study. Clin Oral Investig. 2021 Apr 14. [Read on Pubmed](#)

Silverstein LH, Kurtzman GM, Shatz PC. Suturing for optimal soft-tissue management. J Oral Implantol. 2009;35:82-90. [Read on Pubmed](#)

Silverstein LH. Suturing principles: Preserving needle edges during dental suturing. PPAD. 2005;17:562-564.

Urban IA, Lozada JL, Wessing B, Suárez-López del Amo F, Wang HL. Vertical Bone Grafting and Periosteal Vertical Mattress Suture for the Fixation of Resorbable Membranes and Stabilization of Particulate Grafts in Horizontal Guided Bone Regeneration to Achieve More Predictable Results: A Technical Report. Int J Periodontics Restorative Dent. 2016;36(2):153-159. doi:10.11607/prd.2627 [Read on Pubmed](#)

## creos™ screw fixation

Plonka, A. B., Urban, I. A., & Wang, H. L. (2018). Decision Tree for Vertical Ridge Augmentation. The International journal of periodontics & restorative dentistry, 38(2), 269–275. [Read on Pubmed](#)

Urban, I. A., Monje, A., Lozada, J., & Wang, H. L. (2017). Principles for Vertical Ridge Augmentation in the Atrophic Posterior Mandible: A Technical Review. The International journal of periodontics & restorative dentistry, 37(5), 639–645. [Read on Pubmed](#)

Gultekin, B. A., Cansiz, E., & Borahan, M. O. (2017). Clinical and 3-Dimensional Radiographic Evaluation of Autogenous Iliac Block Bone Grafting and Guided Bone Regeneration in Patients With Atrophic Maxilla. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 75(4), 709–722. https://doi.org/10.1016/j.joms.2016.11.019 [Read on Pubmed](#)

Wessing B, Urban I, Montero E, et al. A multicenter randomized controlled clinical trial using a new resorbable non-cross- linked collagen membrane for guided bone regeneration at dehiscd single implant sites: interim results of a bone augmentation procedure. Clin Oral Impl Res; 2017;28(11):e218–e226. [Read on Pubmed](#)



---

### Order online

Order our complete creos™ range 24 hours a day through the Nobel Biocare online store.

[nobelbiocare.com/store](https://nobelbiocare.com/store)

---

### Order by phone

Call our customer service team or contact your sales representative.

[nobelbiocare.com/contact](https://nobelbiocare.com/contact)



[nobelbiocare.com](https://nobelbiocare.com)



GMT 90639 GB 2406 Printed in the EU © Nobel Biocare Services AG, 2024. All rights reserved. Distributed by: Nobel Biocare.

Disclaimer: Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case, trademarks of Nobel Biocare. Please refer to [nobelbiocare.com/trademarks](https://nobelbiocare.com/trademarks) for more information.

Product images are not necessarily to scale. All product images are for illustration purposes only and may not be an exact representation of the product.

Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office for current product assortment and availability. Caution: Federal (United States) law or the law in your jurisdiction may restrict this device to sale by or on the order of a dentist or a physician. See Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions.

creos™ xenogain is manufactured for/by Nibec Co. Ltd., Chungcheongbuk-do, 27816 Korea and distributed by Nobel Biocare Services AG. creos™ xenoform is manufactured for/by Chiyewon, Gyeonggido, Korea 11927 and distributed by Nobel Biocare Services AG. creos™ syntogain is manufactured for/by Mimetis Biomaterials, Carrer de Cartagena, 245, 3E, Barcelona 08025, Spain and distributed by Nobel Biocare Services AG. creos™ xenoprotect and creos™ mucogain are manufactured for/by Matricel GmbH, Kaiserstrasse 100, 52134 Herzogenrath, Germany and distributed by Nobel Biocare Services AG. creos™ syntoprotect, creos™ syntostitch, creos™ screw fixation are manufactured for/by Osteogenics Biomedical, 4620 71st St # 78, Lubbock, TX 79424, USA and distributed by Nobel Biocare Services AG. creos™ xenofill and creos™ xenofirm are manufactured for/by Collagen Matrix, Inc. 15 Thornton Road Oakland, NJ 07436 USA and distributed by Nobel Biocare Services AG.